Lucy Therapeutics is offering a differentiated and novel approach to drug discovery by drugging targets associated with early disease pathogenesis. LucyTx’s unique approach recognizes that improvement of mitochondrial function early in disease will lead to disease modification as opposed to late-stage symptomatic treatments being pursued by many others. Mitochondrial improvement effects multiple downstream effectors that are essential to disease initiation and progression. Our targets have been validated as neuroprotective in multiple animal models. Key to our strategy is a novel dosing regimen which will mimic effects known to be protective for both neurological and cardiovascular events implicated in key CNS diseases. LucyTx proposes to focus on the orphan disease Rett Syndrome for a proof of concept; we will also explore applications of our technology to Parkinson’s and other CNS diseases.

Education

Biotechnology

Lucy Therapeutics

Amy Ripka

Allen Hopper

Yipeng Du

Vera Procaccia

Minevere Sinani

Robin Grammer

Jessica Garrant

Bryan Keaney

The Scientific Advisors team at Lucy Therapeutics plays a critical role in guiding the company's research and development efforts by providing expert insights and strategic recommendations on mitochondrial-targeted drug discovery. They leverage their extensive knowledge in neurobiology and pharmacology to assess the viability of potential drug candidates and optimize dosing regimens. Additionally, they collaborate with other teams to ensure that the scientific foundation of LucyTx's approach is robust and aligned with the latest advancements in the field, particularly for conditions like Rett Syndrome and Parkinson’s disease.

Scientific Advisors

Research and Development Team

Leadership Team

Scientific Advisors

About

Team members

Other teams at Lucy Therapeutics

Research and Development Team

Leadership Team